drugset
Drugs / CLL1 CAR T-cells
last change Mar 2025 re-read 3 minutes ago

CLL1 CAR T-cells

also known as CLL1 CAR T-cells injection

Cell therapy

Developed for
acute myeloid leukemia
Investigated by
Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine · The Methodist Hospital Research Institute · Yake Biotechnology Ltd. · Zhejiang University

Trials 2

today NCT05252572 · Ph 0 NCT04219163 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05252572 Feb 2022 → Nov 2024 acute myeloid leukemia Zhejiang University Unknown No outcome recorded
Phase 11 trial
Phase 1 NCT04219163 Jul 2020 → Mar 2025 overdue acute myeloid leukemia Baylor College of Medicine Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as CLL-1.CAR T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04219163 ↗
1

NCT05252572 ↗
Known as CLL1 CAR T-cells injection “Other Name: CLL1 CAR T-cells injection” NCT05252572 ↗
Modality Cell therapy “they are called chimeric antigen receptor T-cells or CAR-T cells” NCT04219163 ↗
Route Intravenous “Patients will be given an injection of cells into the vein through an IV” NCT04219163 ↗